February LegalCalls Mass Tort Report

The State of the Docket

February is always a strange month in the mass-tort world. The country feels suspended. Courts are open, but nothing feels dramatic. The Super Bowl, Bad Bunny, Valentine’s Day… and it’s just so cold. The news cycle is distracted. The weeks fly by. And yet, if you slow down and read the dockets instead of the headlines, the first six weeks of 2026 have already reset expectations across the mass tort landscape. This is the time of year when leverage quietly changes hands.

Start with January 29, 2026. The JPML creates MDL No. 3171, centralizing the Lyft passenger sexual assault litigation in the Northern District of California before Judge Rita F. Lin. That did more than tidy up scattered filings. It confirmed that the JPML sees platform safety allegations — including claims that Lyft failed to adequately screen drivers, ignored repeated complaints of predatory conduct, and misrepresented its safety practices to passengers — as coordinated corporate issues, not isolated criminal events. Plaintiffs allege a pattern of assaults and harassment occurring because the company allegedly prioritized growth and convenience over safety measures. The Lyft docket is young. There are no bellwether dates. But for the first time, the runway exists, and that runway will shape discovery and leadership structures.

Seven days later, on February 5, a federal jury in Phoenix delivered the first federal bellwether verdict in the Uber sexual assault litigation. The number: $8.5 million. The theory: apparent agency. The twist: no punitive damages. The jury’s award turned on whether Uber’s control over its platform and representations about safety created a reasonable expectation of protection that the company did not fulfill. Plaintiffs in more than 3,000 pending Uber lawsuits allege Uber failed to conduct adequate background checks, ignored prior incident reports, and delayed implementation of safety features. Sound familiar?  That’s the same allegation as in Lyft. That $8.5 million compensatory verdict is exactly the kind of disciplined number — not a headline-grabbing figure, but a real one — that both sides use to calibrate settlement talks and inventory modeling. Uber has already indicated it will appeal, and the appellate focus will likely center on agency and control in the gig economy. If that verdict survives intact, the Lyft MDL immediately inherits a template for causation and exposure. If it narrows, platform defendants across multiple dockets will recalibrate their models overnight.

That nine-day stretch — January 29 to February 5 — quietly reshaped the platform liability conversation. One company received a centralized forum. Another received a jury number and a live appeal. Appellate briefing will matter. Jury instructions will matter. How courts articulate “control” in a digital marketplace will matter. And every tech-adjacent tort theory watching from the sidelines — from social media design to algorithmic harm — will take notes.

Beyond those cases, a Paraquat case scheduled for trial in Philadelphia settled on the eve of jury selection. The Paraquat MDL still carries thousands of Parkinson’s disease claims, but that settlement offers one of the clearest early indicators of how defendants think about trial risk: once a trial date is imminent, certainty becomes more valuable than unpredictability. Courthouse-steps resolutions like this one travel quickly through mediation and board rooms, recalibrating demand ranges across inventories. This one could be over quick. But it won’t be easy.

The spring calendar is already tightening in other dockets. In the Paragard MDL, bellwether trials are set for March 3 and May 11, 2026. Those dates are circled in red ink. If they proceed, they will generate the first meaningful anchors in a docket that has spent years in discovery and motion practice. A plaintiff verdict can validate theories and boost settlement leverage; a defense verdict can help refine case triage and minimize damages. In mass torts, whether a trial happens can be just as revealing as what the jury ultimately decides.

Pharmaceutical litigation is also edging toward decisive moments. The GLP-1 litigation — involving widely used Ozempic and Wegovy — formally divided into two separate MDLs. One track addresses gastrointestinal injury claims such as gastroparesis and severe stomach paralysis. The other focuses on NAION, a form of sudden vision loss. That split was not cosmetic. It reflects a judicial determination that different injury mechanisms require separate expert discovery and separate causation analysis. The spring and summer of 2026 will be defined by Daubert rulings on general causation in both tracks. If plaintiffs’ experts survive intact, settlement discussions will harden. If the science is narrowed or excluded, valuation will fragment quickly. These are not dramatic courtroom spectacles, but they will determine billions in potential exposure.

The hair relaxer litigation is moving along a similar trajectory in the Northern District of Illinois. Cancer claims tied to long-term chemical straightener use are approaching key expert disclosures and science hearings. Plaintiffs are building epidemiological arguments; defendants are preparing challenges. The court’s rulings on causation will dictate whether that docket gathers settlement momentum or motion practice continues.

What February shows isn’t disorder — it’s that things are starting to sort themselves out. The rideshare litigation now has a federal verdict on the books and an appeal coming. In Paraquat, getting close to trial has clearly pushed real settlement conversations. Paragard finally has bellwether dates set. GLP-1 and the hair relaxer cases are moving toward the science hearings that will shape how they play out.

Key deadlines are lining up — late January, early February, early March, and into May — with Daubert rulings and bellwether picks still ahead. These aren’t just items on a schedule. Verdicts, consolidation decisions, trial dates, and admissibility rulings all move the market in these dockets.

In mass tort work, value tends to jump once the unknowns start getting resolved. The firms that do well in 2026 will be the ones paying close attention to where each litigation actually sits and adjusting their intake around that reality.